Tizanidine Tablet
Product Images NDC 64980-658

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 64980-658). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (356b3e79 D47b 467a Af62 2adca35f1a2f 01)

Chemical structure of tizanidine hydrochloride, showing the molecular framework with chlorine, nitrogen, sulfur atoms, and connected rings typical for tizanidine HCl.*

FDA Label Image

Image (356b3e79 D47b 467a Af62 2adca35f1a2f 02)

A pharmacokinetic line graph showing plasma tizanidine concentration (ng/mL) over time (hours) following a 4 mg oral dose. The graph compares four conditions: tablets with food, tablets without food, capsules with food, and capsules without food, illustrating concentration changes across 24 hours post-dosing.*

FDA Label Image

Image (356b3e79 D47b 467a Af62 2adca35f1a2f 03)

Line graph showing the improvement in Ashworth Score over 6 hours post-dose for 16 mg tizanidine, 8 mg tizanidine, and placebo groups. The graph compares the changes in muscle spasticity at different time points, with error bars indicating variability for each treatment.*

FDA Label Image

Image (356b3e79 D47b 467a Af62 2adca35f1a2f 04)

A line graph depicting improvement in Ashworth Score over three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). Two groups are shown: tizanidine (mean dose 28.8 mg) with square markers and placebo with circle markers, including error bars indicating variability.*

FDA Label Image

Image (356b3e79 D47b 467a Af62 2adca35f1a2f 05)

Label for Tizanidine Tablets, USP 2 mg oral tablets by Rising Pharma Holdings, Inc. The label states each tablet contains 2 mg of tizanidine base and includes storage instructions and a warning that these tablets are not interchangeable with Zanaflex Capsules. The package contains 30 tablets and notes manufacturing by Graviti Pharmaceuticals Pvt. Ltd., India, and distribution from East Brunswick, NJ.*

FDA Label Image

Image (356b3e79 D47b 467a Af62 2adca35f1a2f 06)

Label for Tizanidine Tablets USP 4 mg oral tablets, containing 30 tablets per container. Manufactured by Graviti Pharmaceuticals Pvt. Ltd., India, and distributed by Rising Pharma Holdings, Inc. The label includes storage instructions, a warning that tizanidine tablets are not interchangeable with Zanaflex capsules, and a note to refer to the package insert for prescribing information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.